Pfizer COVID-19 vaccine adult formulation COVID-19 vaccines Main navigation COVID-19 vaccines Pfizer JN.1 COVID-19 vaccine safety data – all participants Pfizer COVID-19 vaccine paediatric formulation (5–11 years) Pfizer XBB.1.5 COVID-19 vaccine Moderna XBB.1.5 COVID-19 vaccine Pfizer bivalent BA.4/5 COVID-19 vaccine Moderna bivalent COVID-19 vaccine Pfizer bivalent BA.1 COVID-19 vaccine Pfizer COVID-19 vaccine adult formulation All participants Aboriginal and Torres Strait Islander participants Adolescent participants People affected by cancer and transplant recipients Pregnant participants Moderna COVID-19 vaccine Novavax COVID-19 vaccine AstraZeneca COVID-19 vaccine Influenza vaccines Mpox (monkeypox) vaccine National Immunisation Program schedule vaccines Nirsevimab RSV vaccines Shingrix As part of the Australian COVID-19 vaccination program, AusVaxSafety is actively monitoring COVID-19 vaccines currently in use in Australia to ensure their ongoing safety. Vaccine safety surveillance through AusVaxSafety occurs in selected vaccination clinics around Australia, including state vaccination hubs, pharmacies, GPs and Aboriginal Community Controlled Health Organisations. Click on the tiles below to view AusVaxSafety COVID-19 vaccine safety data for individuals who received the adult 30 microgram formulation of the Pfizer COVID-19 vaccine. Pfizer COVID-19 vaccine safety data - All participants View the latest safety data here Pfizer COVID-19 vaccine safety data - Aboriginal and Torres Strait Islander participants View the latest safety data here Pfizer COVID-19 vaccine safety data - Adolescent participants View the latest vaccine safety data here Pfizer COVID-19 vaccine safety data - People affected by cancer and transplant recipients View the latest vaccine safety data here Pfizer COVID-19 vaccine safety data - pregnant participants View the latest safety data here COVID-19 vaccines Main navigation COVID-19 vaccines Pfizer JN.1 COVID-19 vaccine safety data – all participants Pfizer COVID-19 vaccine paediatric formulation (5–11 years) Pfizer XBB.1.5 COVID-19 vaccine Moderna XBB.1.5 COVID-19 vaccine Pfizer bivalent BA.4/5 COVID-19 vaccine Moderna bivalent COVID-19 vaccine Pfizer bivalent BA.1 COVID-19 vaccine Pfizer COVID-19 vaccine adult formulation All participants Aboriginal and Torres Strait Islander participants Adolescent participants People affected by cancer and transplant recipients Pregnant participants Moderna COVID-19 vaccine Novavax COVID-19 vaccine AstraZeneca COVID-19 vaccine Influenza vaccines Mpox (monkeypox) vaccine National Immunisation Program schedule vaccines Nirsevimab RSV vaccines Shingrix News & events All news & events 14 July 2025 | News Fewer adverse events reported following NIP pneumococcal vaccine change 03 June 2025 | News New AusVaxSafety data confirms Abrysvo RSV vaccine is well tolerated during pregnancy; adverse events comparable to other maternal vaccinations 18 May 2025 | News 2025 Australian flu season: Who should get a flu shot, which vaccines are available and what to expect in the days following your vaccination 31 March 2025 | News AusVaxSafety commences routine surveillance of 2025 seasonal influenza vaccines